

MANAGEMENT TEAM

Christopher J. Moreau
Chief Executive Officer

Dr. Christopher Bryan, PhD
Vice President Research & Operations

James Kinley, CPA, CA
Chief Financial Officer & Director

Dr. Ahmed Khalil, PhD
Chief Medical Officer

BUSINESS ADVISORY BOARD

U.S. Ambassador (Rtd)
Howard Gutman

MEDICAL & SCIENTIFIC ADVISORY BOARD

Dr. Mark Swaim, MD, PhD

Dr. Jacky Smith, MB, ChB, FRCP, PhD

Dr. Martin Kolb, MD

BOARD OF DIRECTORS

Harry J. F. Bloomfield, QC.

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD

Dr. Mark Williams, PhD.

David Levine

STOCK INFORMATION

(January 19, 2022)

Shares O/S: 1.68 Million

Market Cap: C\$ 18.73 Million

Recent Price: C\$ 11.15

TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGWO

INVESTOR INQUIRIES

Christopher J. Moreau, CEO

604.398.4175

chris@algernonpharmaceuticals.com

HEAD OFFICE

Algernon Pharmaceuticals Inc.
Suite 915-700 West Pender St.
Vancouver, BC, Canada, V6C 1G8

CORPORATE PRESENTATION

COMPANY OVERVIEW

Algernon is a drug repurposing company, investigating drugs that have an established safety history for new disease applications, moving them efficiently and safely into new human trials, and seeking new regulatory approvals in billion dollar global disease markets. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life.

Our program specifically investigates compounds that have never been approved in the U.S. or Europe. We protect our lead compounds with method of use, dosing and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

ALGERNON PHARMACEUTICALS CLINICAL PIPELINE

CANDIDATE	INDICATION	DEVELOPMENT STAGE				
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY REVIEW
Inflammatory Disorders						
IFENPRODIL	Idiopathic Pulmonary Fibrosis & Chronic Cough			Phase 2 Pilot Study Data - Q2, 2022		
Cerebrovascular Disorders						
DMT N, N-DIMETHYLTRYPTAMINE	Stroke		Begin Phase 1 - Q1, 2022			Begin Phase 2 - Acute Stroke Q4, 2022
Oncology						
IFENPRODIL	Pancreatic Cancer		Begin Phase 1 - Q3, 2022			
IFENPRODIL	Small Cell Lung Cancer		Begin Phase 1 - Q3, 2022			

ALGERNON'S LEAD CLINICAL RESEARCH PROGRAMS

IDIOPATHIC PULMONARY FIBROSIS (IPF) AND CHRONIC COUGH

Algernon is investigating lfenprodil in a proof-of-concept Phase 2 human trial to determine the efficacy of lfenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) with chronic cough. There are 7 sites in total participating in the study with 5 located in Australia and 2 in New Zealand.

lfenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF. In addition, lfenprodil significantly both reduced cough frequency and delayed onset in a guinea pig acute cough model.

STROKE

Algernon has established a clinical research program for the treatment of stroke focused on AP-188 ("N,N-Dimethyltryptamine or DMT"), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to investigate DMT for stroke in humans and is planning to begin a Phase 1 clinical trial in Q1, 2022.



RECENT DEVELOPMENTS

DECEMBER 8, 2021

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

DECEMBER 2, 2021

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

NOVEMBER 30, 2021

Algernon Pharmaceuticals Announces New Chief Financial Officer

NOVEMBER 24, 2021

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

NOVEMBER 19, 2021

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

NOVEMBER 1, 2021

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

OCTOBER 21, 2021

Algernon Pharmaceuticals Announces Receipt of CAD\$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market

OCTOBER 13, 2021

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

OCTOBER 08, 2021

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study

[READ MORE NEWS RELEASES](#)

ALGERNON CEO INTERVIEWS



Christopher J. Moreau
Chief Executive Officer

- **PROACTIVE INVESTORS INTERVIEW – ALGERNON PHARMACEUTICALS RECEIVES A POSITIVE RESPONSE FROM U.S. FDA ON SCLC STUDY**
- **UPFRONT WITH ALGERNON PHARMACEUTICALS CEO CHRISTOPHER J MOREAU – EPISODE 4**
- **ALGERNON PRESENTS PSYCHIATRIST AND AUTHOR RICK STRASSMAN, MD ON A SPECIAL BIOPUB WEBCAST HOSTED BY DR. KSS, MD, PHD**
- **PROACTIVE INVESTORS INTERVIEW – ALGERNON PHARMACEUTICALS ESTABLISHES OPTIMUM TREATMENT PERIOD FOR DMT**

ALGERNON IN THE NEWS

- **STREETWISE REPORTS - ALGERNON PHARMACEUTICALS LOOKS TO U.S. FOR HELP FIGHTING STROKES**
- **MARKET ONE – RETHINKING DMT: ALGERNON PHARMACEUTICALS' NOVEL APPROACH TO STROKE TREATMENT**
- **DMT INCREASES GROWTH OF RAT NEURONS BY 40 PERCENT, NEW DATA SHOWS**
- **THE DALES REPORT - PRECLINICAL STUDY SHOWS MICRODOSES OF DMT INCREASED GROWTH OF NEURONS**

ALGERNON YEAR-TO-DATE PRICE HISTORY



[CLICK FOR A REAL TIME QUOTE](#)

RESEARCH CAPITAL
CORPORATION

André Uddin, Ph.D.
Managing Director Healthcare
auddin@mackieresearch.com

Algernon Pharmaceuticals is covered by Research Capital Corporation. Please note that any opinions, estimates or forecasts regarding Algernon Pharmaceuticals' performance made by this analyst, or any other, is theirs alone and do not represent the opinions, forecasts or predictions of the Company.